Interpace Biosciences, Inc.: Combining Molecular Diagnostics, Bioinformatics, and Pathology Services to Revolutionize Cancer Risk Evaluation in the United States Interpace Biosciences, Inc. has been making waves in the United States' medical industry with its innovative molecular diagnostic tests, bioinformatics, and pathology services. The company is dedicated to evaluating cancer risk and providing top-notch diagnosis and prognosis of various types of cancer through its cutting-edge genetic tests. Interpace Biosciences offers a variety of genomic tests, including the PancraGEN for pancreatic cyst and pancreaticobiliary solid lesion diagnosis and prognosis and the PanDNA for limited molecular genetic analysis. The company's ThyGeNEXT test is an extremely important oncogenic mutation panel that allows for the identification of malignant thyroid nodules. Additionally, the company provides ThyraMIR, a proprietary microRNA gene-expression assay that assesses thyroid nodules for their malignancy risk. Interpace Biosciences also offers RespriDx, a genomic test that assists physicians in differentiating between metastatic or recurrent lung cancer. This groundbreaking technology enables healthcare professionals to provide faster and more accurate diagnoses for their patients. Founded in 1986, Interpace Biosciences, Inc. was initially known as Interpace Diagnostics Group, Inc. However, the company rebranded in November 2019 to Interpace Biosciences, Inc. Today, it primarily serves physicians, hospitals, and clinics and is headquartered in Parsippany, New Jersey. With its state-of-the-art services and continually evolving technology, Interpace Biosciences, Inc. is at the forefront of cancer risk evaluation and diagnosis in the United States.